Track market-moving stories before they get noisy

Key Takeaways Acadia Healthcare shares surged 100% YTD as its outlook improved after a sharp 2025 slump.ACHC raised 2026 EBITDA, earnings and operating cash flow guidance while cutting expected capex.Acadia Healthcare added 240 licensed beds through two new joint-venture facilities in Q2 2026. Shares of Acadia Healthcare Company, Inc. (ACHC - Free Report) have surged 100% year to date, marking a sharp rebound from their 2025 slump. Investor sentiment had been weighed down by rising patient-related litigation costs and broader legal and liability concerns, which pressured the stock’s valuation. The industry rose 11.1% so far this year while the S&P 500 gained 13.2%.

YTD Price Performance – ACHC, Industry and S&P 500 Image Source: Zacks Investment Research

Early this year, Acadia brought back former CEO Debra Osteen, replacing Chris Hunter, while reaffirming its 2025 guidance. Investors appeared to welcome Osteen’s return as a potential source of greater operational discipline and stability.

Improving expectations also supported the rally. Management raised its 2026 adjusted EBITDA and earnings outlook following both first- and second-quarter results. After the second quarter, Acadia also increased its operating cash flow guidance to $350-$400 million from $285-$325 million and lowered its expected capital expenditures to $235-$255 million from $255-$280 million. The combination of stronger expected cash generation and lower spending provided additional support, particularly given Acadia’s elevated leverage.

Capacity expansion has also strengthened Acadia’s longer-term growth narrative. The company added 240 licensed beds in the second quarter of 2026 through two newly opened joint-venture facilities, a 144-bed facility with Orlando Health in Florida and a 96-bed facility with Methodist Jennie Edmundson Hospital in Iowa. Acadia also opened two new Comprehensive Treatment Center locations during the quarter.

Improving Estimates for ACHCThe Zacks Consensus Estimate for ACHC’s 2026 earnings is currently pegged at $1.55 per share, which witnessed four upward revisions and no cuts over the past 60 days. The consensus mark for 2027 EPS indicates a further 14.4% year-over-year growth. It beat earnings estimates in each of the past four quarters with an average surprise of 47%.

Meanwhile, the Zacks Consensus Estimate for ACHC’s 2026 and 2027 revenues is pegged at $3.42 billion and $3.61 billion, signaling 3.4% and 5.4% increases, respectively.

Zacks Rank & Key PicksAcadia Healthcare currently has a Zacks Rank #3 (Hold).

Enhancing the array of healthcare options, promising stocks in the Medical sector include Tenet Healthcare Corporation (THC - Free Report) , UnitedHealth Group Incorporated (UNH - Free Report) and The Ensign Group, Inc. (ENSG - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Zacks Consensus Estimate for Tenet Healthcare’s 2026 bottom line suggests 25.4% year-over-year growth. THC has witnessed nine upward estimate revisions over the past 60 days against no movement in the opposite direction. It beat earnings estimates in all the last four quarters, with an average surprise of 22.7%.

The Zacks Consensus Estimate for UnitedHealth’s full-year 2026 earnings indicates a 21.4% year-over-year increase. UNH beat earnings estimates in each of the past four quarters, with an average surprise of 12.1%. The consensus mark for 2026 revenues is pegged at $446.78 billion.

The Zacks Consensus Estimate for Ensign Group’s 2026 full-year earnings implies an 18.6% jump from the year-ago reported figure. ENSG beat earnings estimates in each of the last four quarters, with an average surprise of 4.3%. The consensus mark for its current-year revenues is pegged at $5.88 billion, which indicates a 16.3% year-over-year increase.

Key Takeaways Acadia Healthcare raised 2026 adjusted EBITDA guidance as new facilities exceed expectations.ACHC added 300 beds in the first half of 2026 and remains on track for 500-600 beds.Higher expenses are pressuring margins, while ROE and ROIC remain below industry averages. Acadia Healthcare Company, Inc.(ACHC - Free Report) benefits from strong long-term demand for behavioral health services. The company is expanding its network through joint ventures, de novo facilities and bed additions. Shares of ACHC have surged 113.1% year to date, significantly outperforming the industry’s 13.2% growth during the same period.

Acadia Healthcare has a market capitalization of nearly $2.95 billion. However, the stock appears somewhat expensive relative to its industry peers. ACHC is currently trading at a forward 12-month P/E of 18.17X, higher than the industry average of 11.35X, indicating a premium valuation. ACHC currently carries a Zacks Rank #3 (Hold), along with a Value Scoreof C.

Where Do Estimates for ACHC Stand?The consensus mark for 2026 earnings is pegged at $1.54 per share, which has moved up 4 cents over the past 30 days. The consensus estimate for revenues is pegged at $3.43 billion, indicating 3.5% year-over-year growth. ACHC’s bottom line surpassed estimates in each of the trailing four quarters, the average surprise being 47%.

Acadia Healthcare Company, Inc. Price, Consensus and EPS SurpriseFactors Driving ACHC's PerformanceAcadia is making solid progress in ramping up its recently opened facilities, with revenues and facility-level EBITDA from the 2023-2026 facility cohorts exceeding expectations in the second quarter. It remains confident in generating $200 million of incremental adjusted EBITDA compared with 2025 as these facilities mature. Acadia also raised its 2026 adjusted EBITDA guidance to $590-$615 million from $580-$615 million, supporting its outlook for continued earnings growth.

Acadia continues to expand its network through joint ventures, de novos and bed additions. The company added more than 300 beds during the first half of 2026, including 240 licensed beds from newly constructed facilities in the second quarter. Acadia remains on track to add 500-600 beds in 2026, positioning it to capitalize on sustained behavioral healthcare demand.

Net cash provided by operating activities totaled $223.6 million in the first six months of 2026 compared with $145.0 million in the prior-year period. The company ended the quarter with $171.3 million in cash and cash equivalents and $669.8 million available under its revolving credit facility. Its long-term debt-to-capital ratio of 56.7% remains lower than the industry average of 73.2%, reflecting relatively healthy financial positioning. The company expects positive free cash flow generation in the second half of 2026 as capital expenditures decline to an estimated $235-$255 million. Higher operating cash flow and lower CapEx support financial flexibility.

Risk FactorsAcadia Healthcare continues to face elevated operating and legal expenses, which are pressuring profitability. In the second quarter of 2026, total expenses increased to $843.8 million from $819.2 million in the prior-year period due to higher salaries, wages, benefits, supply costs and professional fees.

Operating expenses also rose to 97.5% of revenues from 94.2% a year ago. Total operating expenses included a $28.6 million PLGL reserve adjustment; excluding this adjustment, operating expenses increased 3.1% year over year. These higher costs could continue to pressure Acadia’s margins and profitability.

ACHC’s profitability and capital efficiency metrics remain below industry averages, reflecting slower returns from recent expansion initiatives. The company’s trailing 12-month return on equity (ROE) was 6.2%, significantly below the industry average of 24.8%. Return on invested capital (ROIC) was 5.5%, below the industry average of 9.4%, indicating weaker return generation despite substantial investments, strong cash generation and valuable real estate assets.

Stocks to ConsiderSome better-ranked stocks in the broader Medical space are Tenet Healthcare Corporation (THC - Free Report) and BrightSpring Health Services, Inc. (BTSG - Free Report) , both sporting a Zacks Rank #1 (Strong Buy) at present, and LifeStance Health Group, Inc. (LFST - Free Report) , carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for Tenet Healthcare’s 2026 earnings is pegged at $19.85 per share, which has witnessed six upward revisions in the past 30 days, with no movement in the opposite direction. THC beat earnings estimates in each of the trailing four quarters, with the average surprise being 22.7%. The consensus estimate for 2026 revenues is pinned at $22.13 billion, implying 3.9% year-over-year growth.

The Zacks Consensus Estimate for BrightSpring Health’s 2026 earnings is pegged at $1.78 per share, which has witnessed five upward revisions in the past 30 days, with no movement in the opposite direction. BTSG beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 16.1%. The consensus estimate for 2026 revenues is pinned at $15.24 billion, implying 18.1% year-over-year growth.

The Zacks Consensus Estimate for LifeStance Health’s 2026 earnings is pegged at 15 cents per share, which has witnessed two upward revisions in the past 30 days, with no movement in the opposite direction. LFST beat earnings estimates in each of the trailing four quarters, with the average surprise being 166.67%. The consensus estimate for 2026 revenues is pinned at $1.71 billion, implying 19.7% year-over-year growth.

Key Takeaways ACHC raised full-year Adjusted EBITDA guidance after Q1 2026 revenues rose 7.6% to $828.8 million.ACHC is prioritizing returns from existing assets and plans 2026 capital spending of $255-$280 million.ACHC is resolving disputes, strengthening compliance, and improving retention. Acadia Healthcare Company, Inc. (ACHC - Free Report) demonstrates how a mission-driven healthcare company can create long-term shareholder value. As the largest standalone behavioral health provider in the United States, operating 275 facilities and more than 12,400 beds across 40 states, Acadia plays a critical role in addressing the nation's growing mental health and addiction treatment needs. Following a challenging period marked by regulatory scrutiny and industry-wide pressures, it has focused on rebuilding operational strength and restoring investor confidence.

Over the past year, management has taken meaningful steps to protect shareholder value. Acadia resolved some legacy billing disputes, worked toward strengthening compliance standards and improving workforce retention, and brought back experienced industry leader Debbie Osteen as CEO. These actions signal a commitment to accountability, operational discipline and long-term value creation.

Acadia's strategy has also evolved. Rather than pursuing growth, it has shifted toward maximizing returns from its existing footprint, limiting planned 2026 capital expenditures to a range of $255 million to $280 million. This strategic shift is evident in the company’s recent results, with first-quarter 2026 revenues rising 7.6% year over year to $828.8 million and management raising its full-year adjusted EBITDA guidance from $575-$610 million to $580-$615 million.

Demand for mental health and addiction treatment continues to rise, supported by growing awareness and significant unmet patient needs. While some historical expansions weighed on returns, many recently developed facilities are approaching maturity. Acadia now has an opportunity to convert years of investment into improved profitability, creating a potential turnaround opportunity for long-term investors.

How Are Competitors Faring?Peers such as Universal Health Services, Inc. (UHS - Free Report) and LifeStance Health Group, Inc. (LFST - Free Report) are also pursuing growth and operational efficiency initiatives.

Universal Health Services is increasingly focused on extracting greater value from its behavioral health network. Alongside efforts to improve occupancy and outpatient growth, UHS recently announced its $835 million acquisition of Talkspace to expand patient access and broaden treatment options.

LifeStance Health continues to strengthen its outpatient mental health platform through clinician expansion and technology-enabled care, reflecting LFST’s efforts to capture a bigger share of the growing demand for behavioral health services.

ACHC’s Price Performance, Valuation & EstimatesShares of Acadia have gained 20.9% over the past year compared to the industry’s 8.4% decline over the same period.

Image Source: Zacks Investment Research

From a valuation standpoint, ACHC trades at a forward price-to-earnings ratio of 15.71X, up from the industry average of 8.45X.  ACHC carries a Value Score of C.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for ACHC’s 2026 earnings is pegged at $1.50 per share, which has moved 1 cent up in the past 60 days.

Image Source: Zacks Investment Research

Acadia currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.